The integration combines Stereotaxis’ magnetic navigation and Robocath’s robotic system, delivering a synergistic endovascular surgery solution. Credit: MAD.vertise / Shutterstock.com.

US medical technology company Stereotaxis has agreed to acquire smart robotic solutions developer Robocath in a deal worth up to $45m.

The acquisition is intended to strengthen Stereotaxis’ position in the sector by expanding its platform to support a wider range of endovascular procedures.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Robocath is projected to contribute approximately $2m in annual revenue in the first post-acquisition year, with the transaction expected to break even in the third year.

The deal includes $20m paid upfront and up to $25m in milestone-based payments, with completion expected in mid-2026.

Based in Rouen, France, Robocath has developed the R-One+ system, currently the only commercially available robotic solution for percutaneous coronary interventions in Europe, with 15 installations worldwide.

The company is advancing a next-generation system intended to allow simultaneous manipulation of up to five interventional devices, with initial first-in-human procedures completed in France.

The deal will combine Stereotaxis’ magnetic navigation with Robocath’s mechanical robotic system, delivering a synergistic solution for endovascular surgeries.

Stereotaxis also plans to fast-track development of Robocath’s next-generation system, aiming to file for US and European regulatory clearance within two years while integrating additional hardware and software capabilities.

Stereotaxis chairman and CEO David Fischel said: “Robocath represents a highly strategic addition to Stereotaxis, amplifying and accelerating our strategy as the leading robotic platform for the broad spectrum of endovascular procedures.

“By combining our complementary robotic mechanisms, we are creating a uniquely capable platform that expands our reach across interventional medicine.

“This transaction accelerates our strategy, enhances our technological leadership, provides attractive commercial synergies, opens new avenues for growth, and supports other strategic opportunities being pursued by Stereotaxis.”

Earlier this month, Stereotaxis launched the Synchrony system for cath laboratories after receiving 510(k) clearance from the US Food and Drug Administration.

The system is designed to advance digital capabilities in interventional cath labs.